AIDS-associated lymphoma is a type of lymphoma that develops as a result of severe immune system deterioration caused by HIV infection. Lymphoma is a cancer arising from the uncontrolled proliferation of lymphocytes — one of the immune system’s key cell types.
Why Does HIV/AIDS Increase the Risk of Lymphoma?
In a healthy immune system, T cells keep abnormal cell proliferation in check. When HIV destroys these cells, immune surveillance weakens, leaving the body vulnerable to cancer cells. In addition, oncogenic viruses frequently co-occurring with HIV infection — such as Epstein-Barr virus (EBV) and HHV-8 — can also trigger lymphoma development.
Main Types
Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type. Although aggressive in behavior, it can respond to treatment.
Burkitt Lymphoma is an extremely fast-growing, high-grade lymphoma with a strong association with EBV. It requires intensive chemotherapy.
Primary Central Nervous System Lymphoma (PCNSL) is a severe form involving the brain and spinal cord, seen in patients with very low CD4 counts. It is almost universally EBV-positive.
Primary Effusion Lymphoma (PEL) is a rare type characterized by fluid accumulation in the pleural, peritoneal, or pericardial cavities. It is associated with HHV-8.
Plasmablastic Lymphoma is an aggressive form with plasmacytic features that frequently involves the oral cavity.
Symptoms
Although the symptom pattern varies by type and site of involvement, commonly encountered findings include “B symptoms” — night sweats, fever, and weight loss — enlarging lymph nodes in the neck, armpits, or groin, abdominal pain or swelling, neurological symptoms (in PCNSL), and general malaise and fatigue.
Diagnosis
Biopsy is essential for diagnosis. In addition, staging is performed with computed tomography (CT) or PET-CT, CD4 count and HIV viral load are measured, and bone marrow biopsy may be included in the evaluation.
Treatment
Treatment rests on two fundamental pillars.
Antiretroviral therapy (ART) must be maintained to strengthen the immune system and suppress HIV. The use of ART directly enhances the effectiveness of lymphoma treatment.
Chemotherapy: The most widely used regimen is R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). More intensive protocols are applied for Burkitt lymphoma. In PCNSL, methotrexate-based regimens and radiotherapy may come into play.
Prognosis
Before ART became widespread, AIDS-associated lymphomas carried an extremely poor prognosis. Today, effective ART allows better preservation of immune function, improves chemotherapy tolerance, and has led to markedly better survival rates. That said, prognosis varies considerably depending on the lymphoma type, stage, CD4 count, and the patient’s overall condition.
This content is intended for informational purposes only. A physician should always be consulted for any diagnostic or treatment decision.